Cerebral toxoplasmosis can present in patients who are immunosuppressed, particularly in those with AIDs with CD4 counts lower than 100. Patients typically respond to therapy, but cerebral toxoplasmosis can be fatal if left untreated. One of the typical treatment options for this disease is Pyrimethamine and sulfadiazine. Folate supplementation should also be administered due to pyrimethamine’s effect on folate metabolism. Amphotericin B can be used for mucormycosis. Itraconazole can be used for blastomycosis. Albendazole +/- dexamethasone can be used in neurocysticercosis. This patient has immunosuppression from kidney transplant rejection medications, not from AIDs, and thus HAART therapy is not indicated.